Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aggressive polychemotherapy for acute myelofibrosis.

B Hertenstein1, E Kurrle, N Frickhofen

  • 1Abteilung Innere Medizin III, Medizinische Universitätsklinik Ulm, Fed. Rep. Germany.

European Journal of Haematology
|April 1, 1990
PubMed
Summary

Acute myelofibrosis, a rare malignant disorder of the megakaryocytic lineage, shows promising response to aggressive polychemotherapy. This treatment approach is feasible and induces significant remission rates in affected patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A resonance sonorheometry guided dose reduction of plasma transfusion in repetitive hip surgery in a patient with a severe factor XI deficiency: a case report.

Anaesthesia reports·2024
Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023
Same author

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Leukemia·2019
Same author

[Acute exacerbation of chronic CLL with multiple pathological fractures : A rarity].

Der Unfallchirurg·2018
Same author

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Annals of hematology·2017
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Acute myelofibrosis is a rare and poorly understood hematologic malignancy.
  • Evidence suggests it originates from the megakaryocytic lineage, closely resembling acute megakaryocytic/blastic leukemia.

Purpose of the Study:

  • To investigate the nature of acute myelofibrosis.
  • To evaluate the efficacy of aggressive polychemotherapy in treating acute myelofibrosis.

Main Methods:

  • Morphological observation, immunophenotyping, and ultrastructural analysis were employed.
  • Eleven patients with acute myelofibrosis were treated with combination polychemotherapy regimens (daunorubicin, cytosine arabinoside, 6-thioguanine or VP16-213).

Main Results:

Related Experiment Videos

  • The study supports acute myelofibrosis as a malignant disorder of the megakaryocytic lineage.
  • Treatment resulted in 4 complete remissions, 2 partial remissions, and 1 minor response.
  • The duration of aplasia was not significantly increased.

    • Conclusions:

    • Aggressive polychemotherapy is a feasible and effective treatment strategy for acute myelofibrosis.
    • This therapeutic approach can achieve significant remission rates in patients with this rare disease.